[Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases]. [electronic resource]
Producer: 20130722Description: 37-43 p. digitalISSN:- 0040-3660
- Adult
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis -- drug therapy
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Murine-Derived -- adverse effects
- Arthritis, Rheumatoid -- drug therapy
- Female
- Genetic Engineering
- Humans
- Immunologic Factors -- adverse effects
- Infliximab
- Lupus Erythematosus, Systemic -- drug therapy
- Male
- Remission Induction -- methods
- Rheumatic Diseases -- drug therapy
- Rituximab
- Severity of Illness Index
- Treatment Outcome
No physical items for this record
Publication Type: Controlled Clinical Trial; English Abstract; Journal Article
There are no comments on this title.
Log in to your account to post a comment.